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Background: Variability of response to statins has been related to polymorphisms in genes involved in cholesterol
homeostasis and statin metabolism, such as CYP3A4 and CYP3A5. We investigated the effects of atorvastatin on
CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and on CYP3A activity and their interactions with
common variants.
Methods: Unrelated individuals (n = 121) with hypercholesterolemia (HC) were treated with atorvastatin
(10 mg/day/4 weeks). Ninety-twonormolipidemic (NL) subjectswere selected as a control group. Genotype anal-
ysis of CYP3A4*1B (rs2740574), CYP3A4*22 (rs35599367), CYP3A5*3C (rs776746), and CYP3A5*1D (rs15524) and
mRNA levels in peripheral blood mononuclear cells (PBMCs) were estimated. CYP3A activity was phenotyped by
the urinary cortisol to 6-beta-hydroxy-cortisol ratio.
Results: LDL cholesterol reduction in response to atorvastatin was positively correlated with change in CYP3A4
(R2 = 0.039, p = 0.037) and CYP3A5 (R2 = 0.047, p = 0.019) mRNA levels and negatively correlated with
CYP3A activity (R2 = 0.071, p = 0.022). CYP3A5*3C (AGT haplotype) was associated to lower basal CYP3A5
mRNA expression in HC (p b 0.045), however none of the haplotype groups impacted treatment.
Conclusion: It is likely that cholesterolemia status changes promoted by atorvastatin play a role in regulating
CYP3A4 and CYP3A5 mRNA expression in PBMCs, as well as CYP3A activity. CYP3A5*3C (AGT haplotype) also
contributes for the variability of CYP3A5 mRNA levels in PBMCs.© 2013 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Statins are reversible inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA
reductase, which catalyzes the rate-limiting step in the de novo biosyn-
thesis of cholesterol by acetyl-CoA [1]. Reduction of intracellular choles-
terol subsequently induces the expression of the low-density lipoprotein
(LDL) receptor, resulting in increased LDL uptake by hepatic and periph-
eral cells, thereby dramatically reducing circulating cholesterol levels [2].
Pleiotropic effects include improving endothelial function, decreasingToxicological Analyses, School
. Prof. Lineu Prestes, 580, B17,
0.
e and Pathology, Mayo Clinic,
 OA license. vascular inﬂammation and enhancing plaque stability [3]. Statin use
contributes to an approximate 30% reduction in cardiovascular disease
(CVD) [4], and statins are one of the most commonly prescribed drugs
worldwide.
Atorvastatin is administered orally as an active acid form and is me-
tabolized primarily by cytochrome P450 3A4 (CYP3A4) and CYP3A5 in
the gut and liver, and it is further conjugated by uridine diphosphate
glucuronosyl transferases 1A1 and 1A3 [5]. The uptake and efﬂuxmem-
brane drug transporters expressed in liver and intestinal cells contrib-
ute to the overall bioavailability of the atorvastatin [5–7].
CYP3A4 and CYP3A5 are important drug metabolizing enzymes
due to their abundance in the intestinal epithelium and liver, and
their ability to metabolize a large number of chemically unrelated drugs
[8]. Inter-individual variability in CYP3A4 and CYP3A5 liver expression
is very high (10- to 100-fold). This variability has been suggested to be as-
sociated with variants in the genes encoding CYP3A4 and CYP3A5 and
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cluding atorvastatin and other statins [9,10].
There is also great interindividual response to statin treatment.
It is thought that genetics may play an important role in the
biodisposition and safety of statins [11]. Understanding and addressing
the pharmacogenomic variability of statins has been challenging and
numerous efforts have been undertaken to discover a surrogate marker
for statin response to treatment.
CYP3A4 and CYP3A5 expression and activity in the liver are major
determinants of drug efﬁcacy, toxicity, and hence, therapeutic outcome
[10]. Hepatocytes are themain site of action for statins. Increased CYP3A
mRNA expression and CYP3A protein levels in hepatocytes have been
demonstrated to be increased by statins [12], ranging from 6 to 20
fold the basal level [13,14]. Moreover, CYP3A4mRNAexpressionwas in-
creased when HepG2 cells were incubated with atorvastatin, as was
CYP3A5, though to a lesser extent [15].
Analysis of mRNA expression in peripheral blood mononuclear cells
(PBMCs) has been used to evaluate the effects of lipid-lowering drugs
on peripheral tissues in vivo [16,17]. Considering their involvement in
pathophysiological mechanisms of cardiovascular-related diseases,
mainly through the inﬂammatory pathways, expression in mononu-
clear cells could be used to evaluate modiﬁcation of expression ob-
served with this system [18].
In this study, we investigated the effects of atorvastatin on
PBMCs CYP3A4 and CYP3A5 mRNA expression and CYP3A activity
in vivo, measured by 6-beta-hydroxy-cortisol/cortisol ratio, and evaluat-
ed the interaction with common genetic variants of CYP3A4 and CYP3A5
in hypercholesterolemic individuals.
2. Subjects and methods
2.1. Subjects and study protocol
The characteristics of this study design and protocol have been
previously reported [16,19,20]. Brieﬂy, 458 individuals were selected
to participate in the study at two clinical research centers in Sao
Paulo, Brazil. Participantswere screened anddetermined to behypercho-
lesterolemic (HC) with LDL cholesterol levels higher than 160 mg/dL
(n = 210) or normolipidemic (NL; n = 248). Participants with hyper-
triglyceridemia (triglycerides ≥ 400 mg/dL), hypothyroidism, diabetes
mellitus, liver or kidney diseases, and other forms of secondary dyslip-
idemiawere excluded from this study. Overall 121HC and 92NL individ-
uals consented and completed the study protocol. HC patients went
through a low fat diet (according to American Heart Association Step
One Diet) for four weeks [21]. Individuals who still had LDL cholesterol
greater than 160 mg/dL were treated with atorvastatin 10 mg orally
once daily for four weeks. HC patients were evaluated for serum concen-
trations of lipids to assess response to atorvastatin treatment, and alanine
aminotransferase (ALT) and creatine kinase (CK) to monitor liver and
muscle toxicity side effects. Patients continued taking othermedications
throughout the study, including diuretics, angiotensin converting en-
zyme (ACE) inhibitors, beta-adrenergic blockers, and calcium channel
blockers.
Information on age, body mass index (BMI), blood pressure, men-
opause status, hypertension, obesity, family history of cardiovascular
disease (CVD), tobacco smoking, alcohol consumption, exercise and
current medications were recorded.
The study protocol was approved by the Ethics Committees of the
Dante Pazzanese Institute of Cardiology, University Hospital and School
of Pharmaceutical Sciences at the University of Sao Paulo, Sao Paulo,
Brazil.
2.2. Samples
Blood samples were collected after a 12 hour fast. Patients under-
going atorvastatin treatment had blood drawn prior to and after the4 week treatment. Serum total cholesterol, high-density lipoprotein
(HDL) cholesterol and triglycerides were measured using routine enzy-
maticmethods. CK andALTweremeasured by kineticmethods. LDL and
very low-density lipoprotein (VLDL) cholesterol were calculated [22].
Plasma apolipoprotein AI (apoAI) and apolipoprotein B (apoB)were de-
termined by nephelometry.
Morning urine samples were collected. Urinary creatinine was
measured by the Jaffe method. An aliquot was frozen at −80 °C for
6-beta-hydroxy-cortisol (6BOHC) and cortisol detection by high perfor-
mance liquid chromatography (HPLC).
2.3. CYP3A4 and CYP3A5 genotyping
Genomic DNA was isolated from 1 mL EDTA-anticoagulated whole
blood samples using a salting-out method [23]. CYP3A4*1B (rs2740574)
was detected by polymerase chain reaction (PCR) followed by restriction
fragment analysis (RFLP) as previously published [24]. CYP3A5*3C
(rs776746) and CYP3A4*22 (rs35599367) were detected using TaqMan
GenotypingAssays [Life Technologies (Foster City, CA), catalog numbers
C__26201809_30 and C_593013445_10]. Each PCR reaction contained
4 μL of UniversalMasterMix (2×) (Life Technologies), 0.4 μL of the spe-
ciﬁc Genotyping Assay (20×), and 20 ng of DNA. The real-time PCR as-
says were carried out in 96-well plates using a 7500 Real-Time PCR
system (Applied Biosystems, Foster City, CA, USA). The thermal cycling
protocol consisted of an initial cycle of 10 min at 95 °C followed by
40 cycles at 92 °C for 15 s, 60 °C for 1 min using standard 7500 condi-
tions. CYP3A5*1D (rs15524) was detected by DNA sequencing. Primer
sequences and PCR thermal cycling conditions were previously pub-
lished [20].
For quality control purposes, 5% of all samples were repeated and
genotype accuracy was conﬁrmed by DNA sequencing using the cap-
illary electrophoresis systemMega BACE 1000 (Amersham Pharmacia
Biotech, Upsala, Sweden) after PCR ampliﬁcation using sets of primers
designed with Primer Premier® v. 5.0 (Premier Biosoft International,
USA).
2.4. RNA extraction and CYP3A4/CYP3A5 mRNA expression by real-time
PCR
EDTA-anticoagulated blood was diluted in phosphate-buffered
saline (1:1) and this suspension was layered in Histopaque-1077
(Sigma-Aldrich, St. Louis, MO, USA) and centrifuged for 30 min at
400 g at room temperature. PBMCs were collected from the inter-
phase and immediately underwent RNA extraction using TRIzol® re-
agent (Invitrogen Corporation, CA, USA) according to themanufacturer's
instructions.
Complementary DNA (cDNA) was produced from 1 μg of total RNA
by SuperScriptTM II Reverse Transcriptase RNaseH-with 10 μMrandom
primers (Invitrogen Corporation, CA, USA) and CYP3A4 and CYP3A5
mRNA were measured by a TaqMan quantitative PCR assay.
The reference gene was chosen after analysis using the software
geNorm [25]. Five reference genes were tested [hypoxanthine
phosphoribosyl transferase I (HRPT1), hydroxymethyl-bilane synthase
(HMBS), beta-2-microglobulin (B2M), glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and ubiquitin C (UBC)]. The most stable gene for
PBMCs under experimental conditions was GAPDH, so it was used as a
reference gene. The real-time PCR assays were carried out in 96-well
plates using a 7500 Real-Time PCR system (Applied Biosystems, Foster
City, CA, USA). CYP3A4 primer sequences were: F: TCAATAACAGTC
TTTCCATTCCTCAT and R: TTCGAGGCGACTTTCTTTCATC, and the probe
sequence was FAMTM TGTTTCCAAGAGAAGTTACMGBNFQ. For CYP3A5,
primers were F: CTATCGTCAGGGTCTCTGGAAATT and R: ACGTTCCC
CACATTTTTCCATA and the probe sequence was FAMTMACACAGAGT
GCTATAAAAMGBNFQ. For GAPDH, primers were F: GGAAGGTGAAG
GTCGGAGTCA, R: CTGGAAGATGGTGATGGGATTTC and the probe was
VIC®TCAGCCTTGACGGTGC MGBNFQ. The thermal cycler protocol
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all real-time PCR assays was considered adequate if between 90% and
110%, established by a standard curve of different cDNA dilutions and
their slopes (Efﬁciency = 10(−1/slope) − 1). Samples were tested in
duplicate. All reaction plates were tested with no template controls in
order to evaluate possible contamination of the reagentswith PCR prod-
ucts. The relative expression of the target gene was analyzed using a
comparative ΔCT method [26].
2.5. CYP3A activity assay: 6-beta-hydroxy-cortisol/cortisol ratio
Cortisol to 6BOHC ratio was used as a marker to measure CYP3A
activity. Samples were collected any time from 6 am to 9 am (in
order to minimize the effect of the circadian rhythm on urinary excre-
tion of the analytes). Samples were evaluated for quality using a uri-
nary creatinine assay (NL, 101 ± 60; HC at baseline 78 ± 55; HC
after treatment 66 ± 47 mg/dL). Cortisol and 6BOHC were measured
by HPLC after liquid–liquid extraction of the urine samples based on a
previously reported protocol [27]. Brieﬂy, all reagents used for testing
were HPLC-grade and were purchased fromMerck (Merck, Sao Paulo,
Brazil). The standards for cortisol, 6BOHC, and the internal standard
(dexamethasone) were purchased from Sigma Aldrich (Sao Paulo,
Brazil) and were of at least 98% purity. The standard solutions were
prepared in HPLC-grade methanol at 1 mg/mL. The solutions were
stable for up to 3 months when stored at −20 °C. 200 μL of dexa-
methasone [1 mg/mL] was added to 500 μL of urine samples and
homogenized by vortexing. Subsequently, 5 mL of dichloromethane
were added. After mixing vigorously for 1 min, the solution was
centrifuged for 5 min at 3200 g. The organic phase was removed and
the solution evaporated at 40 °C under a nitrogen stream. Then, the
sample was reconstituted with 200 μL of methanol and water (60:40,
v/v). Assays were carried out using a LC-2010 HT gas chromatographer
(Shimadzu Brazil, Sao Paulo, Brazil) with Luna 5 mm C18 100A
150 × 4.6 mm columns (Phenomenex Inc, Torrance, CA, USA). The
chromatography was performed at room temperature with 60 μL of
sample, an injection ﬂow rate of 1.0 mL/min, and a mobile phase
containing methanol and water (60:40, v/v). Detection was set at
UV absorbance (245 nm) and resultswere expressed as 6BOHC/cortisol
ratio.
Analytical recovery was carried out by adding 100 ng of cortisol and
1000 ng 6BOHC in 500 μL of 1:50 diluted urine before the extraction
procedure (n = 6). Creatinine on the diluted urine was 1.6 mg/dL
and before the sample was spiked with the analytes of interest, it did
not yield any detectable peaks on the chromatogram. The recovery
was 92% ± 8% for dexamethasone (mean ± SD), 85% ± 7% for cortisol
and 81% ± 12% for 6BOHC. The limit of quantitation (LOQ) was 1 μg/L
for cortisol and 1 mg/L for 6BOHC. The limit of detection (LOD) was
1 μg/L for cortisol and 100 μg/L for 6BOHC. The estimated accuracy
was 105% for cortisol and 78% for 6BOHC. The linearity range was
1–400 μg/L (r2 = 0.9932) for cortisol and 1–500 mg/L (r2 = 0.9931)
for 6BOHC. The internal standard was used as a pre-analytical control
and its peak area was used to assess the variability of the process.
Runswere acceptedwhen recovery of the internal standardwas greater
than 85%. Peaks were quantitated using 6BOHC/cortisol peak area ratio.
2.6. Statistical analysis
Categorical variables were compared by the Fisher's exact test.
The quality of the CYP3A4*1B, CYP3A5*3C, CYP3A5*1D genotypes
were assessed using the Pearson's χ2 test of deviation from Hardy–
Weinberg equilibrium of SNPs of control (or case or both) subjects.
Minor allele frequencies were compared between NL and HC sub-
jects using the Fisher's exact test. Pair-wise linkage disequilibrium
(LD) among SNPs was measured using the D′ index and r2 values.
Haplotype frequencies, overall haplotype associations and pair-wise
haplotype associations compared to the wild-type haplotype (deﬁnedas AGT) were assessed using the HaploStats analysis package in R
[28,29]. Linear regression analysis was performed to examine associa-
tions between haplotypes and mRNA expression and activity both ad-
justed for possible covariates and unadjusted.
Continuous variables were presented as mean ± standard deviation
(SD) ormedian (range), as appropriate. NL andHC comparisonswere an-
alyzed by t-test or Wilcoxon rank sum test, as appropriate. Comparisons
of continuous variables before and after atorvastatin treatment were an-
alyzed by pairedWilcoxon signed rank test. Reduction in serum lipids in
response to atorvastatin treatment were expressed as the value after
treatment − the value before treatment. Associations amongmRNA ex-
pression, activity, and individual SNPswere assessed using univariate lin-
ear regression on the log-transformed variables. Univariate general linear
regressionwas used todetermine possible covariates for and associations
with LDL-c reduction.
CYP3A4 and CYP3A5 expression can be considered a complex trait
under multifactorial control [10], so multiple linear regression analysis
wasused to determinewhich variables could affect or predictmRNAex-
pression. From those variables with univariate associations with mRNA
expression, CYP3A activity and response to atorvastatin treatment,
multiple linear regression models were used for assessing additional
genotype effects and covariates using SAS® software (version 9.2,
SAS Institute Inc.). Signiﬁcance was deﬁned as p-value b 0.05.
3. Results
The characteristics of the HC and NL groups are described in Table 1.
Both groups had the same proportion of female and male subjects en-
rolled (p = 0.297). NL subjects (n = 91) were younger than the HC
subjects (n = 119) (about 10 years in average (p b 0.0001)). In both
groups, Caucasians represented themajority (p = 0.552). BMI and obe-
sity were higher in HC individuals (both p b 0.017). NL and HC subjects
had approximately the same rate of hypertension (p = 0.091), but fam-
ily history of CVD was higher in HC (p = 0.036). Exercise, tobacco and
alcohol consumption were similar between both groups (p > 0.47).
Since the HC group is older than the NL group, the menopause status
in women from the HC group was also higher (p b 0.0001). NL and
HC subjects had similar proﬁles of concomitant medication usage,
such as CYP3A inhibitors and substrates (p > 0.16, Table 1).
HC subjects had higher levels of total and LDL cholesterol, triglycer-
ides, and apoB, and lower levels of apoAI than NL (p b 0.0001). HDL-
cholesterol levels were similar between the two groups (p = 0.56).
Atorvastatin signiﬁcantly reduced total, LDL cholesterol, apoB, and tri-
glycerides levels (p b 0.0001) (Table 1), and lowered high-density lipo-
protein (HDL) cholesterol levels. In addition, atorvastatin treatment did
not cause a signiﬁcant increase in CK or ALT levels (data not
shown). Univariate general linear regression analysis showed that
LDL-cholesterol reduction in response to atorvastatin was not
inﬂuenced by age, gender, ethnicity, BMI, hypertension, CVD history,
menopause status, and concomitant medications (CYP3A substrates or
inhibitors) (p > 0.14, Table 2). On the other hand, exercise explained
4.2% of the LDL cholesterol reduction (Table 2).
CYP3A4 (Fig. 1A) and CYP3A5 (Fig. 1B) mRNA baseline levels in
PBMCs were lower in HC than in NL groups (p b 0.0001). For HC sub-
jects, CYP3A4 and CYP3A5mRNAexpressionwas signiﬁcantly correlated
before (R2 = 0.22, p b 0.0001) and after atorvastatin treatment (R2 =
0.58, p b 0.0001), as determined by linear regression. Baseline levels of
CYP3A4 and CYP3A5 mRNA expression levels were not inﬂuenced by
BMI, ethnicity, gender, hypertension, CYP3A concomitant substrates or
inhibitors (p > 0.089) (data not shown). However, both CYP3A4 and
CYP3A5 mRNA expression levels at baseline were inversely associated
with exercise (p b 0.017), while only CYP3A5mRNA expression was in-
versely associated with family history of CVD (p = 0.025, data not
shown).
Average mRNA levels of CYP3A4 and CYP3A5 were not inﬂuenced
after atorvastatin in HC individuals (p > 0.169) (Fig. 1), nevertheless
Table 1
Data of hypercholesterolemic and normolipidemic individuals.
Variable NL (91) HC basal (119) P value1 HC Atorva (119) P value2
Age, years 47 ± 8 57 ± 11 b0.0001a –
Men 28% (25) 35% (42) 0.297c –
Caucasian 64% (55) 68% (81) 0.552c –
Body mass index, kg/m2 26 [18,39] 27 [17,38] 0.017 b –
Obesity 11% (10) 27% (32) 0.008c –
Hypertension 47% (42) 59% (69) 0.091c –
Family history of CVD 43% (38) 58% (68) 0.036 c –
Exercise 51% (45) 46% (48) 0.566 c –
Tobacco smoking 17% (15) 22% (23) 0.469 c –
Alcohol comsumption 30% (27) 31% (33) 1.000 c –
Menopause status 32% (17) 85% (53) b0.0001c –
Concomitant medication
CYP3A inhibitors 14% (12) 8% (8) 0.160c –
CYP3A substrates 16% (13) 17% (18) 0.844c –
CYP3A inducers 0% (0) 0% (0) 1.000 c –
None 78% (66) 80% (82) 1.000 c –
Lipid proﬁle, mg/dL
Total cholesterol 174 [130,200] 273 [218, 414] b0.0001b 196 [120, 268] b0.0001d
Triglycerides 82 [39, 151] 143 [50, 379] b0.0001b 126 [34, 381] 0.0001d
HDL cholesterol 54 [36, 91] 54 [30, 99] 0.560b 52 [27, 94] 0.0002d
LDL cholesterol 101 [45, 131] 181 [144, 319] b0.0001b 114 [67, 188] b0.0001d
Apolipoprotein AI 141.5 [68, 207] 126.5 [40, 218] 0.0001b 128 [81, 230] 0.067d
Apolipoprotein B 76 [32, 129] 136 [67, 198] b0.0001b 95.5 [59, 151] b0.0001d
Minor allele frequency
CYP3A4*1B rs2740574 [G] 33% 20% 0.049c –
CYP3A4*22 rs35599367 [T] 3% 1% 0.621c
CYP3A5*3C rs776746 [A] 33% 29% 0.538c –
CYP3A5*1D rs15524 [C] 30% 26% 0.367c –
Number of individuals is in parenthesis. Obesity was considered as BMI ≥ 30 kg/m2. Hypertension was blood pressure higher than 140/90 mm Hg or treatment with anti-hypertensive drugs
[41]. Exercise was 30 min of aerobic activity at least three times a week. Current tobacco smokingwas a daily intake of one ormore cigarettes. Alcohol consumption was deﬁned as one dose a
dayor less. A standard alcohol dose contains approximately 10 g of alcohol and its volume varies according to the beverage (350 mL of beer, 150 mL ofwine or 50 mLof distilled spirits [42].
CVD: cardiovascular disease; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
Continuous variables are shown as median and interquartile range, compared by t-test (a) or Wilcoxon rank sum test (b). Categorical variables were compared by Fisher Exact test (c).
Wilcoxon Signed Rank Sum test (d).
1 p-value refers to comparison between NL and HC basal groups.
2 p-value refers to comparison between HC basal and treatment with atorvastatin.
Table 2
Univariate linear regression analysis of variables associated with LDL cholesterol reduc-
tion in response to atorvastatin.
Variables N Slope (SE) p-value R2
Age, years 119 −0.149 (0.251) 0.554 0.003
Men 119 8.145 (5.822) 0.164 0.016
Caucasian 119 2.606 (6.013) 0.666 0.002
Hypertension (mm Hg) 116 −4.137 (5.687) 0.468 0.005
Obesity (BMI > 30 kg/m2) 117 −0.272 (6.322) 0.966 b0.0001
Body mass index 117 0.266 (0.656) 0.686 0.001
Family history of CVD 118 −8.455 (5.672) 0.139 0.019
Exercise 104 12.679 (5.967) 0.036 0.042
Tobacco smoking 106 10.346 (7.233) 0.156 0.019
Alcohol consumption 106 5.040 (6.483) 0.439 0.006
Menopause status 62 3.457 (11.457) 0.764 0.002
CYP3A inhibitors 103 5.728 (11.366) 0.615 0.003
CYP3A substrates 103 −6.776 (7.992) 0.398 0.007
CYP3A4 mRNA change [2−DDCt] 113 0.541 (0.256) 0.037 0.039
CYP3A5 mRNA change [2−DDCt] 115 1.269 (0.535) 0.019 0.047
6BOHC/Cortisol ratio change (*) 74 −0.077 (0.033) 0.022 0.071
CYP3A4*1B[ref genotype AA] 119 0.774 0.004
GG 2.720 (10.273) 0.792
AG −4.169 (6.805) 0.541
CYP3A5*3C[ref genotype GG] 119 0.051 0.05
AA 9.150 (9.461) 0.336
AG −11.321 (5.850) 0.055
CYP3A5*1D[ref genotype TT] 119 0.086 0.04
CC −10.332 (5.997) 0.088
CT 9.777 (9.781) 0.320
Notes: CVD: cardiovascular disease; 6BOHC: 6-beta-hydroxy-cortisol; SE: standard
error of slope. (*) Calculated as ratio after atorvastatin minus ratio at baseline.
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and CYP3A5mRNAexpression after treatment is related to a greater LDL
cholesterol reduction in response to atorvastatin (Table 2, p b 0.037).
These variables explain, respectively, 3.9% and 4.7% of the LDL cholesterol
reduction. Variation in CYP3A5mRNA expression remained signiﬁcantly
associated with LDL reduction, even after adjusting for exercise or
change in 6BOHC/cortisol (p b 0.043) (data not shown).
Noneof the variables tested (BMI, hypertension, CVDhistory, gender,
age, ethnicity, concomitant medication or menopause status) affected
urinary 6BOHC/cortisol ratio before (p > 0.081) and after treatment
(p > 0.10) (data not shown).
6BOHC/cortisol ratio showed lower values in HC subjects than in the
NL group (p b 0.0001) (Fig. 2) and was inﬂuenced by age (p = 0.049),
but not by other variables (p > 0.081, data not shown). There was no
correlation between 6BOHC/cortisol ratio and PBMC CYP3A4 or CYP3A5
mRNA levels in NL or HC subjects in this study (p > 0.331, data not
shown).
Even though atorvastatin treatment did not modify 6BOHC/cortisol
ratio in HC subjects (Fig. 2), univariate linear regression showed that
LDL cholesterol reduction in response to atorvastatin was negatively
correlated and partly explained (7.1%) by 6BOHC/cortisol ratio change
(p = 0.022, Table 2) even after adjustment for exercise (data not
shown).
Genotype distribution of the studied polymorphisms were in HWE
(p > 0.158), except for CYP3A4*1B (p = 0.006). The minor allele fre-
quency (MAF) of the CYP3A4*1B allele was slightly higher in NL (33%)
than in HC (20%, p = 0.049), while CYP3A4*22, CYP3A5*3C, and
Fig. 1. CYP3A4 (A) and CYP3A5 (B) mRNA levels for NL subjects and HC before and after atorvastatin treatment (10 mg/day/4 weeks). NL, normolipidemic subjects. HC, hypercho-
lesterolemic subjects. Mean is represented as a cross (+), median as a hyphen (−) in the jitterplot. mRNA expression of each gene was measured by qPCR and normalized with
GAPDH. Y axis is on log scale. The 2−DCt formula was used to calculate the relative amount of transcript in the sample.
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(Table 1).
Differences in CYP3A4 and CYP3A5 allele frequencies were observed
between Caucasians (whites) (MAF: CYP3A4*1B [G], 0.08; CYP3A4*22
[T], 0.03; CYP3A5*3C [A], 0.15 and CYP3A5*1D [C], 0.16) and Afro-
descents (MAF: CYP3A4*1B [G], 0.55; CYP3A4*22 [T], 0.00; CYP3A5*3C
[A], 0.60 and CYP3A5*1D [C], 0.50) (p b 0.0001). However, this variable
is based in skin color, which does not correlate well with ancestry in
populations with a large genetic diversity such as ours [30–32].
Linkage disequilibrium was tested for CYP3A4 and CYP3A5 variants.
Association was found for CYP3A4*1B and CYP3A5*3C, D′ = 0.7202
(p b 0.0001, r2 = 0.37). An even stronger association was observed
for CYP3A5*3C and CYP3A5*1D, D′ = 0.9136 (p b 0.0001, r2 = 0.73).
No linkage disequilibrium was found between CYP3A4*22 and the
other variants (D′ = −1.000 (p > 0.0611).
CYP3A4*1B and CYP3A5*1D genotypes were not associated with
LDL cholesterol reduction in response to atorvastatin (Table 2). The
CYP3A5*3C reference genotype GG was very close to being signiﬁcant
(p = 0.051) and alone explained 5% of the LDL cholesterol reduction.
Haplotype groups were formed based on the number of copies of
each variant: CYP3A4*1B (A > G), CYP3A5*3C (A > G) and CYP3A5*1DFig. 2. Urinary 6BOHC/cortisol ratio in NL and HC individuals before and after atorva-
statin treatment (10 mg/day/4 weeks). Notes: NL, normolipidemic subjects. HC, hyper-
cholesterolemic subjects. 6BOHC, 6-beta-hydroxy-cortisol. Mean is represented as a
cross (+), median as a hyphen (−) in the jitterplot. Cortisol and 6BOHC were mea-
sured in morning urine samples by HPLC-UV. Y axis is on log scale.(C > T), respectively, with AGT as the reference, since it was the most
frequent haplotype in our sample. CYP3A4*22 was not included for this
analysis due to its low frequency. The frequencies of the haplotypes
AGT, AAC, GAC, GAT, GGT and rare (AAT and AGC: less than 2%) were
similar between NL and HC groups (p = 0.1460, data not shown).
Univariate association analysis was assessed between CYP3A4
and CYP3A5 haplotypes and other variables in HC subjects. Ethnicity
was the most strongly associated (p b 0.0001), as shown by allelic
analyses. The relationship between CYP3A4/3A5 haplotypes and mRNA
expression was carried out after adjusting for covariates (including but
not limited to gender, ethnicity, hypertension, CVD history, and BMI)
using the HaploStats package in R [28]. All HC patients had posterior
probabilities of the assigned haplotype > 96%.
CYP3A4 mRNA expression at baseline or post-treatment was not
inﬂuenced by CYP3A4 and CYP3A5 haplotype in HC individuals (p =
0.887, data not shown). Interestingly, GAC and GAT haplotypes were as-
sociatedwith higher CYP3A5mRNAbasal levels in PBMCs comparedwith
AGT haplotype in the HC group (pair-wise p = 0.0003 and p = 0.045,
respectively, Fig. 3A). This relationship did not remain after treatment
with atorvastatin (p = 0.919, Fig. 3B).
CYP3A4 and CYP3A5 haplotypes were not related to baseline or
post-treatment levels of urinary 6BOHC/cortisol ratio, even when ad-
justed for covariates (data not shown).
4. Discussion
Our observations demonstrated that LDL reduction in response to
atorvastatin is explained by exercise as well as variation in CYP3A4 and
CYP3A5 mRNA expression and CYP3A activity. CYP3A4 SNPs were not
signiﬁcantly associated to atorvastatin response. It is well established
that an active lifestyle reduces cardiac risk and decreases lipid levels.
Exercising regularly led to an additional reduction of 13% in LDL-c levels
in our HC subject cohort.
Previous reports regarding the impact of CYP3A4 and CYP3A5mRNA
expression and activity on atorvastatin treatment have been variable
[15,33,34]. Although median values of CYP3A4 and CYP3A5 expression
were apparently not inﬂuenced by atorvastatin due to their well
known great variability (ten- to 40-fold variation in CYP3A4 liver
mRNA expression has been reported [10,35]), the linear regression
analysis showed that an increase in CYP3A4 and CYP3A5 mRNA ex-
pression levels was positively correlated to the reduction of LDL choles-
terol. Therefore, a relationship between cholesterolemia and CYP3A4
and CYP3A5 mRNA expression in response to atorvastatin treatment
was demonstrated. On the other hand, LDL cholesterol levels of HC sub-
jects after treatment were still higher than in NL subjects, which might
Fig. 3. Relationship of CYP3A5 haplotypes with mRNA levels at baseline (A) and after atorvastatin treatment (B) in hypercholesterolemics. Haplotype analysis was performed using
HaploStats software. mRNA expression of each gene was measured by qPCR and normalized with GAPDH. The 2−DCt formula was used to calculate the relative amount of transcripts
in the sample. Y axis is on log scale. Median values for each haplotype are represented as a hyphen (−) in the jitterplot. Haplotypes were formed in the following order: CYP3A4*1B,
CYP3A5*3C and CYP3A5*1D. Reference haplotype was considered as the most frequent one, AGT.
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not increase up to the NL levels. A relevant aspect of this ﬁnding is
that a greater decrease in LDL cholesterol levels (i.e. better response to
treatment) was associated with a greater increase in CYP3A4 and
CYP3A5 mRNA expression (positive slope). An increase in CYP3A4
and CYP3A5 mRNA levels would lead to enhanced atorvastatin activa-
tion and consequently, a greater LDL-c reduction would take place.
The urinary 6BOHC/cortisol ratio reﬂects CYP3A activity in the liver
after renal clearance for cortisol and its metabolite. The 6BOHC/cortisol
ratio is advantageous in that it requires only an isolated urine sample
and it is the only currently available non-invasive assay for CYP3A activ-
ity. Moreover, it has been suggested that thismethod is accurate enough
for detecting drug induction or inhibition when the subjects are their
own controls [36]. Given that CYP3A4 and CYP3A5 have overlapping
substrates, an assay hasnot yet beendeveloped that can tease out the ac-
tivity of CYP3A4 and CYP3A5 individually.
Overall, HC presented with lower 6BOHC/cortisol ratios when com-
pared to NL subjects (Fig. 2) suggesting that CYP3A activity is lower in
HC subjects. As reported byHonda and colleagues (2011) in hepatocytes
[37], cholesterol is a substrate for 4-β-hydroxylation by CYP3A4. The
product of that reaction, 25-hydroxy-cholesterol, is a potent HMG-CoA
reductase inhibitor in vitro, and therefore, CYP3A may participate in
the regulation of lipid metabolism [37]. A consequence of the fact that
cholesterol is a substrate for CYP3A4 is that it may function as an inhib-
itor of the enzyme's activity [38]. Shinkyo and colleagues [39] have
reported that cholesterol acts as a substrate and inhibitor of CYP3A4 in
hepatocytes by binding to CYP3A4 and, at 10 μM, inhibitingCYP3A4 pro-
totypic reactions. Therefore, the lower CYP3A activity levels found in HC
subjects may be explained by the higher levels of serum cholesterol in
those patients. Furthermore, using linear regression, we demonstrated
that CYP3A activitywas inversely correlated to the reduction of LDL cho-
lesterol in response to atorvastatin.
While the 6BOHC/cortisol ratio reﬂects the endogenous activity of
CYP3A4 and CYP3A5, interactions between CYP enzymes and their li-
gands are often atypical. There is more than one mode of binding and
conformational changes upon binding of some substrates [38]. One
could hypothesize that, after the patients were given atorvastatin—
that has a high afﬁnity to CYP3A4/5, it would become the enzymes'
ﬁrst priority to metabolize the drug, with a lower priority given to
their endogenous role of cortisol hydroxylation. This could explainwhy we observed an association of lower levels of CYP3A activity in
HC subjects after LDL-c reduction.
More than a decade ago, it was stated that 90% of the variation in
CYP3A4 activity was attributable to genetic factors [40]. It is intriguing
that despite multiple groups' efforts in pharmacogenomic studies, the
keystone for explaining the interindividual variability observed in the
expression of CYP3A4 has yet to be identiﬁed. It has been suggested
that the remaining heritable variability hitherto unexplained might be
due to epigenetic regulation, not evaluated in this report. Or yet,
as suggested by Wang et al. [34], the impact of the variants could
be tissue-speciﬁc and inﬂuence mRNA and protein expression just
in the liver, for instance. We used a candidate gene strategy to eval-
uate the relationship between individual polymorphism and haplo-
types of CY3A4 and CYP3A5 with mRNA expression in PBMCs. To
the best of our knowledge, the haplotype analyses as performed in
this study were not previously reported. Interestingly the haplo-
types GAT and GAC, but not the individual variants, were associated
with increased CYP3A5 expression in HC patients. Baseline CYP3A5
mRNA expression was lower in AGT than in GAC or GAT haplotype
carriers in HC subjects, conﬁrming the CYP3A5*3C (middle G in the
AGT haplotype) deleterious effect on CYP3A5 expression. CYP3A5*3C
abolishes a splice site and creates a pseudoexon, thereby generating sev-
eral non-coding mRNAs and a non-functional truncated protein. It is
unclear as to why there is a difference in CYP3A5 mRNA expression in
the HC group at baseline, but not after atorvastatin treatment. One hy-
pothesis is that treatment with atorvastatin, and its accompanying
pleiotropic effects may activate transcription factors and/or other
biological pathways that compensate for the deleterious effect of
CYP3A5*3C. Further investigations would be required to explore
this hypothesis.
It is likely that the high variability in CYP3A4 and CYP3A5mRNA ex-
pression, as well as CYP3A activity, complicated the observation of ator-
vastatin effects. The wide range of response to atorvastatin treatment in
a genetically diverse population such as ours created a heterogeneous
HC group. Furthermore, a lack of liver biopsies from these patients hin-
dered the ability to correlate the PBMC ﬁndings to the liver. Future
studies in larger cohorts of patients will be necessary to reproduce
and correlate PBMC ﬁndings with liver specimens. Future studies may
further beneﬁt from examining the effects of haplotypes in conjunction
with other variations in other genes, such as the ones that code for
163M.A.V. Willrich et al. / Clinica Chimica Acta 421 (2013) 157–163phase II enzymes and efﬂux transporters such as SLCO1B1 and ABCB1, in
order to better understand the impact of the combined variants on re-
sponse to atorvastatin treatment.
In conclusion, this study reports that changes in cholesterolemia
status promoted by statins inﬂuence expression of CYP3A4 and CYP3A5
mRNA in PBMCs and affect CYP3A activity in different ways.
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